# TAU V337M Research Report **Protein:** TAU V337M **Variant:** V337M **UniProt ID:** P10636 **Disease Association:** Alzheimer's disease **Report Generated:** 2026-07-14 01:46 UTC **AlphaFold Confidence (pLDDT):** 55.0% **Structure Folded:** 2026-07-09 --- ## Structure Summary TAU is a protein that normally helps stabilize the cellular scaffolding in brain cells, but in Alzheimer's disease it forms toxic tangles. This study used computer modeling (AlphaFold2) to predict the 3D structure of a variant called V337M, which changes one building block in the protein. The very low confidence score (55.0) indicates that this variant likely makes the protein highly disordered and flexible—a state that may promote the abnormal clumping seen in Alzheimer's disease. --- Tau protein normally binds to microtubules (cellular scaffolding structures) to stabilize them in neurons. The V337M variant changes valine to methionine at position 337, located in a region that influences tau's behavior. This study used AlphaFold2 to predict the structure of this variant, producing a model with an average confidence (pLDDT) of 55.0, which indicates poor structural definition across most of the protein. The extremely low confidence score suggests this variant exhibits substantial structural disorder, meaning the protein lacks a stable, well-defined 3D shape. Recent research has revealed that tau aggregation into beta-sheet fibrils—the toxic tangles that define Alzheimer's disease and related tauopathies—is a complex process involving multiple structural states [3]. Intrinsically disordered regions in tau are thought to facilitate both its normal microtubule-binding function and its pathological tendency to aggregate under disease conditions. The V337M substitution introduces a longer, sulfur-containing methionine residue where a smaller valine normally resides, potentially altering local flexibility and aggregation propensity. Post-translational modifications and mutations in tau significantly influence its role in Alzheimer's disease neuropathology and cognitive decline [2]. While the computational prediction cannot definitively establish whether V337M promotes aggregation without experimental validation, the high degree of disorder predicted here is consistent with conformational states that may be vulnerable to misfolding. Studies examining tau pathology across neurodegenerative diseases have identified shared molecular mechanisms, including genomic damage patterns in affected neurons [1], suggesting that structural disruptions in tau could have broad consequences for neuronal health. The V337M variant has not been extensively characterized in the literature as a known pathogenic mutation, unlike more commonly studied variants such as P301L. Genetic studies of tau pathology have increasingly employed advanced approaches including rare variant analyses to identify genes and modifications that influence cerebral tau deposition [4]. Without high-confidence structural data or functional studies, it remains uncertain whether V337M directly contributes to disease or represents a rare variant of unclear significance. The predicted disorder may reflect either a pathological state or limitations in modeling this particular sequence variant. ## Works Cited [1] Zhou et al. (2026). Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders. Cell. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42385702/) [2] Libby et al. (2026). Post-translational modifications in the brain are critical contributors to Alzheimer's disease neuropathology and cognitive decline. bioRxiv : the preprint server for biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42327232/) [3] El et al. (2026). Structures and Dynamics of Tau Assemblies from Solid-State NMR. Accounts of chemical research. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42283695/) [4] Gunasekaran et al. (2026). Common and rare variant analyses implicate JARID2 in cerebral tau deposition. NPJ dementia. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42404994/) ## Similar Research **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.** Gerlando et al. (2026) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/) --- ## Clinical Data ### ClinVar - **Classification:** Pathogenic - **Review Status:** criteria provided, multiple submitters - **Last Evaluated:** 2026-01-01 ### gnomAD Not found in gnomAD. --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | frontotemporal dementia | 0.789 | genetic_literature, clinical, literature, genetic_association, animal_model | | Pick disease | 0.757 | literature, animal_model, genetic_association, genetic_literature | | supranuclear palsy, progressive, 1 | 0.725 | literature, animal_model, genetic_association, genetic_literature | | Progressive supranuclear palsy - parkinsonism | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Atypical progressive supranuclear palsy | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Classical progressive supranuclear palsy | 0.696 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy-parkinsonism syndrome | 0.647 | animal_model, genetic_association, genetic_literature | | late-onset Parkinson disease | 0.639 | literature, animal_model, genetic_association, genetic_literature | | semantic dementia | 0.639 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy | 0.614 | genetic_literature, clinical, literature, genetic_association, animal_model | *...and 3339 more associations* --- ## Agent Findings ### Literature (1) - **2026-07-09:** None of the provided papers directly address the TAU V337M variant specifically. While several papers discuss tau pathology mechanisms, genetic risk factors, and biomarkers relevant to Alzheimer's disease pathogenesis, they focus on other variants (P301L, PSEN1 mutations, APOE variants, PRNP variants) or general tau biology. These papers provide contextual understanding of tau-mediated neurodegeneration but do not offer specific insights into the V337M variant's pathogenic mechanisms or clinical associations. ### Clinical (1) - **2026-07-09:** ### Structural (1) - **2026-07-10:** AlphaFold structure update: Baseline check: 9 structure(s) found ### Synthesis (1) - **2026-07-10:** Synthesis of 5 findings (clinical, literature, peptides, structural, supplements): The TAU V337M variant associated with Alzheimer's disease presents a multifaceted therapeutic landsc... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)